Genome-wide transcriptome analysis identifies novel gene signatures implicated in human chronic liver disease

Rana V Smalling1, Don A Delker, Yuxia Zhang

  • 1Dept. of Medicine and Huntsman Cancer Institute, Univ. of Utah School of Medicine, Salt Lake City, Utah, 84132. l.wang@hsc.utah.edu.

Insights

This study identifies novel genes regulated by small heterodimer partner (SHP) involved in chronic liver disease progression. These findings offer new insights into the molecular mechanisms of liver diseases like cirrhosis and nonalcoholic steatohepatitis.

Area of Science:

  • Hepatology and Molecular Biology
  • Genomics and Transcriptomics
  • Nuclear Receptor Signaling

Background:

  • The progression of human liver disease to cirrhosis involves complex molecular mechanisms that are not fully understood.
  • Small heterodimer partner (SHP/Nr0b2), a nuclear receptor, acts as a hepatic tumor suppressor, and its reduced expression in cirrhotic livers suggests a role in disease pathogenesis.
  • Identifying SHP-regulated genes is crucial for understanding chronic liver disease development.

Purpose of the Study:

  • To identify novel genes regulated by SHP that contribute to the development and progression of chronic liver disease.
  • To elucidate the molecular pathways influenced by SHP in liver disease pathogenesis.
  • To provide a comprehensive transcriptomic profile of SHP-deficient livers in the context of liver disease.

Main Methods:

  • Comprehensive RNA sequencing (RNA-seq) analysis of Shp(-/-) mice.
  • Comparison of mouse RNA-seq data with human hepatitis C cirrhosis RNA-seq and nonalcoholic steatohepatitis (NASH) microarray datasets.
  • Validation of identified genes in 126 human liver specimens and mouse models of liver injury using quantitative PCR (qPCR).

Main Results:

  • Discovery of new gene signatures associated with chronic liver disease and regulated by SHP.
  • Identification of several key genes, including peptidoglycan recognition protein 2, dual specific phosphatase-4, tetraspanin 4, thrombospondin 1, and SPARC-related modular calcium binding protein-2, upregulated in liver disease.
  • Validation of these genes' physiological relevance across various human liver conditions (steatosis, fibrosis, NASH, cirrhosis) and mouse models.

Conclusions:

  • This study identifies novel SHP-regulated genes implicated in the molecular pathogenesis of human chronic liver diseases.
  • The findings provide valuable transcriptome information for characterizing the mechanisms underlying liver disease progression.
  • The identified genes represent potential targets for future therapeutic strategies in liver disease management.